Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06217081
Other study ID # EM-05-015029
Secondary ID 59MDW-23000524-A
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date April 2024
Est. completion date July 2025

Study information

Verified date March 2024
Source 3M
Contact Doug Flashinski, MN, RN
Phone 6127992643
Email dflashinski@solventum.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to generate safety and performance data for 3M™ Topical Tissue Adhesive. Enrolled subjects with qualifying trauma lacerations or surgical incisions will be randomized to receive 3M™ Topical Tissue Adhesive or Histoacryl® Blue Topical Skin Adhesive with follow-up visits at 10 days and 30 days after application of tissue adhesive.


Description:

This is a multicenter, prospective, open-label, randomized, non-inferiority study that will include 452 randomized Subjects requiring closure of superficial lacerations, clean traumatic lacerations, low-tension incisions, or surgical incisions from minimally invasive surgeries. The study will enroll Subjects from up to 10 sites in the USA. Subjects will be seen during Screening (no more than 10 days before application of tissue adhesive), on the day in which skin edges of wound(s) are reapproximated and tissue adhesive is applied (Day 0), 10 days after application of the tissue adhesive, and 30 days after application of the tissue adhesive.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 452
Est. completion date July 2025
Est. primary completion date June 2025
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 22 Years and older
Eligibility Inclusion Criteria: - Subject is at least 22 years of age on the date of informed consent - Subject or Subject's legally authorized representative can provide informed consent - Subject is willing and able to attend all scheduled study visits and abide by all study restrictions - Subject has a single laceration that is = 100 mm (10.0 cm) in length or up to 4 surgical incision(s), each = 100 mm (10.0 cm) in length, defined as Class I or Class II wound(s), in which the use of a tissue adhesive (in combination with but not replacing deep dermal sutures, if applicable) is appropriate, including the following: - surgical incision from a minimally invasive surgery - low tension incision - superficial laceration - clean, traumatic laceration with edges that can be easily approximated Exclusion Criteria: - Subject has a positive pregnancy test within 48 hours prior to randomization at Day 0 or is lactating prior to randomization at Day 0 - Subject is found to have any of the following before randomization: - a known peripheral vascular disease - a history of hypertrophic scarring and/or keloids - any Class III or Class IV wounds - uncontrolled diabetes mellitus (DM), defined as HbA1C = 10% within 90 days before screening. If HbA1C data is unavailable or the Subject presents in an emergency situation, uncontrolled DM will be defined as blood glucose = 250 mg/dL - a known blood clotting disorder - immunocompromised - a known systemic or local bacterial, viral, or fungal infection - critical injury - condition(s) that in the opinion of the Investigator will impact study results (eg, hemophilia or autoimmune disorder) or the ability of the Subject to remain compliant with study procedures, study restrictions, and/or visits - Subject has a known hypersensitivity or allergy to any of the components of study products (eg, polyoxamides or cyanoacrylates) - Subject is concurrently participating in or was enrolled in another interventional clinical study within 30 days of randomization - Subject has a laceration or incision that is > 100 mm (10 cm) in length - Subject has any incision that is within 5 cm of any adjacent incision - Subject has one of the following: - a "burst" or stellate laceration - wound with exposed bone - wound with suspected skin edge ischemia due to extensive undermining - wound requiring drain(s) - wound requiring a conventional closure method (eg, subcuticular/intradermal suture, staples, adhesive strips) OR subcuticular stitch placement for enhanced wound support (ie, to further minimize tension) - Subject has a wound with any of the following etiologies: - human or animal bite - prolonged pressure (ie, decubitus) - Subject has a wound in any of the following anatomical locations: - on mucosal surfaces or across mucocutaneous junctions (eg, oral cavity, lips) - in or around the eyes - an anatomical area that is under tension or over a joint - on an area that may be regularly exposed to body fluids or with dense natural hair present (eg, scalp)

Study Design


Intervention

Device:
3M Topical Tissue Adhesive
Application of investigational topical tissue adhesive to trauma laceration or surgical incision.
Histoacryl® Blue Topical Skin Adhesive
Application of control topical tissue adhesive to trauma laceration or surgical incision.

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
3M The University of Texas Health Science Center at San Antonio, United States Department of Defense

Outcome

Type Measure Description Time frame Safety issue
Other Vancouver Scar Scale Validated tool to assess cosmesis on wounds at 30 days after application of tissue adhesive. Scores range from from 0 (best) to 13 (worst) 30 days
Primary Apposition of skin edges Percentage of subjects with wounds with 100% apposition of skin edges at 10 days after application of tissue adhesive 10 days
Secondary Tissue adhesive remaining Percentage (%) of the sum of the subject's wound length(s), in relation to the sum of the original incision/laceration length(s), with tissue adhesive remaining at 10 days after application of tissue adhesive 10 days
Secondary Apposition of skin edges Percentage of subjects with wounds with 100% apposition of skin edges at 30 days after application of tissue adhesive 30 days
See also
  Status Clinical Trial Phase
Recruiting NCT04081792 - Optimal Antibiotics for Operated Diabetic Foot Infections N/A
Recruiting NCT02685761 - Skin Incisions and Wound Complication Rates for C-sections in Obese Women N/A
Completed NCT01297322 - RESPECT Trial - (Rapid Extravascular Sealing Via PercutanEous Collagen ImplanT) N/A
Not yet recruiting NCT03872544 - Short Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Completed NCT03193021 - AMBULATE: Cardiva Mid-Bore VVCS vs. Manual Compression for Multiple Femoral Venous Access Sites, 6 - 12F ID N/A
Not yet recruiting NCT06028854 - Blood Characteristics and Abdominal Emergency Surgery
Completed NCT05646121 - Suprasorb® A + Ag in the Treatment of Wounds at Risk of Infection and Infected Wounds
Enrolling by invitation NCT03880188 - Long Term Status of Free Dermal Fat Autografts for Complex Craniofacial Wounds
Recruiting NCT06342479 - Discharge Training for Patients With Intertrochanteric Fracture N/A
Recruiting NCT04994145 - A Post-Market Clinical Investigation on Mepilex Border Post-Op
Recruiting NCT03561376 - Zinc Oxide Versus Petrolatum Following Skin Surgery Early Phase 1
Recruiting NCT04439552 - fMRI and IVCM Cornea Microscopy of CXL in Keratoconus
Completed NCT05618912 - Scar Appearance After Postoperative Hydrocolloid Dressing Versus Standard Petrolatum Ointment N/A
Completed NCT04596163 - Transversus Thoracis Muscle Plane Block for Sternotomy Pain in Cardiac Surgery N/A
Completed NCT04036344 - Buddy Relationships in DermatoloGic Excisions for Skin Cancer N/A
Completed NCT05791721 - Effect of Preemptive Etoricoxib and Dexamethasone on Wound Healing and Clinical Parameters After Third Molar Surgery Phase 4
Recruiting NCT06073678 - Photobiomodulation in Palate Wounds: Somatosensorial Evaluation N/A
Withdrawn NCT04053946 - Clinical Assessment of Next Science Wound Gels in Healing Below the Knee Amputation Surgical Wound Compared to SOC N/A
Completed NCT05252260 - Comparison of Diode Laser-Assisted Vestibuloplasty And Conventional Vestibuloplasty N/A
Recruiting NCT04740775 - LiquiBand® Exceed™ and LiquiBand® Rapid™ for General Surgery Procedures N/A